NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis

Rigel Pharmaceuticals, Inc. (RIGL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RIGL

$48.67

+$0.17 (+0.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RIGL with… →

RIGL Key Statistics

As of Sep 4, 2026
Trading
Open
$48.04
Previous Close
$48.50
Day's Range
47.77–48.87
52-Week Range
24.95–52.24
Volume
104.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.20
Valuation
Market Cap
$909.15M
P/E Ratio
2.88
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.85
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.28
EPS (ttm)Profit attributable to each share over the last twelve months.
16.89
Financials (FY)
Revenue (FY)
$294.28M+64.15%
Net Income (FY)
$367.02M+1999.08%
Profit marginThe share of revenue left as profit after all costs and taxes.
116.30%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
18.68M
1-Year Return
+21.28%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
346.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RIGL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.64%
2025+154.64%
2024+16.00%
2023−3.33%
2022−43.40%
2021−24.29%
2020+63.55%
2019−6.96%
2018−40.72%
2017+63.03%
2016 (partial year)−19.87%

As of September 4, 2026.

RIGL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$294.28M$367.02M124.7%
2024$179.28M$17.49M9.8%
2023$116.88M−$25.09M−21.5%
2022$120.24M−$58.57M−48.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$294.28M$274.66M$125.47M$367.02M124.7%
2024$179.28M$160.63M$24.19M$17.49M9.8%
2023$116.88M$109.77M−$20.49M−$25.09M−21.5%
2022$120.24M$118.49M−$54.23M−$58.57M−48.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RIGL Valuation vs Biotechnology Median

Median of 656 stocks
MetricRIGLBiotechnology medianvs median
P/E2.8812.570.2x the median
P/S ratio3.2815.260.2x the median
Profit margin116.30%0.00%116.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rigel Pharmaceuticals, Inc. (RIGL) is capitalised at $909.15M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 172.

RIGL last closed at $48.67 on September 4, 2026. That is +$0.17 (+0.35%) against the previous close. Over the past 52 weeks the price has ranged from $24.95 to $52.24. The latest close sits 95.07% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $294.28M. Against the prior fiscal year total of $179.28M, that is a change of +64.15%. Net income for the same year was $367.02M. That is +1,999.08% against the prior fiscal year. The reported profit margin is 116.3%. That is 116.3 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 16.89.

Across the 4 fiscal years on file, revenue moves from $120.24M in 2022 to $294.28M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 2.88 times earnings. That is 0.2 times the Biotechnology median of 12.57. The forward P/E on file is 9.85. Measured against sales, the shares trade at 3.28 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +21.28%. Across 10 years the annualized return works out at +3.65%. The reported beta is 1.2. Daily returns over the trailing 10 years annualize to a volatility of 81.17%.

Growth & Income

No dividend is on file for RIGL.

2026 is still running; the price is +13.64% year to date. Across the complete calendar years on file, 2025 returned +154.64% and 2022 returned −43.40%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Rigel Pharmaceuticals, Inc. (RIGL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rigel Pharmaceuticals, Inc. RIGL $909.15M 2.9
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rigel Pharmaceuticals, Inc. trades at a P/E of 2.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Visit website →